Fibroma of tendon sheath is a benign tumor that presents as a small subcutaneous nodule that slowly increases in size. The tumors often have a multinodular growth pattern, with individual nodules being composed of bland, slender, spindle-shaped cells (myofibroblasts) in a dense, fibrous matrix.” A common microscopic finding is the presence of elongated, slit-like blood vessels. The lesions nearly always arise in the distal portions of the extremities. They often occur on the fingers, hands, toes, or feet. Although they are benign, they may recur in up to 40% of cases.Although they may be regarded as a tumor of the skin, the lesions arise from tendons and aponeuroses in superficial sites, and are therefore properly classified as in the category "soft tissue tumor." The World Health Organization, 2020, reclassified these tumors as a specific, benign tumor type in a broad category of soft tissue neoplasms termed fibroblastic and myofibroblastic tumors.The biological nature of Fibroma of tendon sheath is not known, but the category appears to comprise a number of different pathologic processes. It is considered that about one-third of the lesions in this category may be acral variants of the entity, nodular fasciitis. See also
Giant cell tumor of the tendon sheath
List of cutaneous conditions


== References ==
Since neurologic and developmental difficulties have not been reported as a consequence of neuroblastoma or its treatment, it is thought that these are exclusively due to the immune mechanism underlying OMS.One study concludes that: "Patients with OMA and neuroblastoma have excellent survival but a high risk of neurologic sequelae. Favourable disease stage correlates with a higher risk for development of neurologic sequelae. The role of anti-neuronal antibodies in late sequelae of OMA needs further clarification".Another study states that: "Residual behavioral, language, and cognitive problems occurred in the majority". Research
The National Institute of Neurological Disorders and Stroke (NINDS) conducts and supports research on various movement disorders, including opsoclonus myoclonus. These studies are focused on finding ways to prevent, treat, and cure these disorders, as well as increasing knowledge about them. Nomenclature
OMS was first described by Marcel Kinsbourne in 1962. (The term Opsoclonus was coined by Orzechowski in 1913, but it was classically described and associated with neuroblastoma by Kinsbourne). Other names for OMS include:
Dancing Eyes-Dancing Feet syndrome
Dancing Eyes syndrome (see also Nystagmus)
Kinsbourne syndrome
Myoclonic Encephalopathy of Infants (MEI), not to be confused with Early myoclonic encephalopathy (EME)
Opsoclonic Cerebellopathy
Opsoclonus-Myoclonus-Ataxia (OMA)
Paraneoplastic Opsoclonus-Myoclonus Ataxia (POMA)

References
Further reading


== External links ==